NASDAQ:NBP

Novabridge Biosciences Q2 2026 Earnings Results & Report

Novabridge Biosciences logo
$0.82 +0.03 (+3.89%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.84 +0.01 (+1.67%)
As of 07:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novabridge Biosciences reported Q2 2026 earnings on August 20, 2026. The company reported EPS of -$0.1610.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Novabridge Biosciences EPS Results

Actual EPS
-$0.1610
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novabridge Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Novabridge Biosciences Q2 2026 Earnings FAQ

Novabridge Biosciences (NASDAQ:NBP) reported earnings of -$0.1610 per share for Q2 2026. The report was announced on Thursday, August 20, 2026.

Novabridge Biosciences Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Brokers Offer Predictions for NBP FY2026 Earnings
See More Novabridge Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novabridge Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novabridge Biosciences and other key companies, straight to your email.

About Novabridge Biosciences

Novabridge Biosciences (NASDAQ:NBP) (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival.

The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets. These products remain in clinical development and are not necessarily approved for commercial use.

Novabridge Biosciences was founded in 2016 and historically maintained operations and development activities in both China and the United States. The company has since emphasized a more globally oriented, U.S.-focused development strategy while continuing to advance selected oncology programs through clinical studies and potential strategic partnerships. Dr. Joan Shen, a biopharmaceutical executive and physician, is the company’s founder and has served in senior leadership roles.

View Novabridge Biosciences Profile